




RealRate

PHARMACEUTICAL 2020

Imunon Inc.
Rank 227 of 358





RealRate

PHARMACEUTICAL 2020

Imunon Inc.
Rank 227 of 358



The relative strengths and weaknesses of Imunon Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Imunon Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Imunon Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is 26%, being 9.9% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	16,235
Cost of Goods Sold	0
Intangible Assets	2,317
Liabilities, Current	7,894
Liabilities, Non-Current	1,144
Other Assets	19,321
Other Compr. Net Income	13
Other Expenses	-1,816
Other Liabilities	14,681
Other Net Income	1,897
Other Revenues	500
Property and Equipment	405
Research and Development	13,065
Selling, General and Administrative Expense	8,000

Output Variable	Value in 1000 USD
Assets	38,278
Liabilities	23,719
Expenses	19,249
Revenues	500
Stockholders Equity	14,559
Net Income	-16,852
Comprehensive Net Income	-16,845
Economic Capital Ratio	26%